Innoviva, Inc. (INVA) stock forecast and price target
Price $19.03 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($19.03)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $0.86 | — | $435M |
| Next fiscal year ends December 31, 2027 | $2.14 | — | $475M |
| Next quarter ends December 31, 2026 | $0.45 | — | $111M |
| Quarter after ends March 31, 2027 | $0.49 | — | $113M |
Consensus of the analysts covering Innoviva, updated daily.
Our model vs. Wall Street
Analysts see 82.9% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Innoviva’s intrinsic value about 177% above today’s market value, and it scores 3.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Innoviva stock price target?
The average 12-month target from 5 analysts is $34.80, 82.9% above the current price of $19.03 Targets range from $18.00 to $46.00.
Is Innoviva a buy according to analysts?
The consensus rating is “Buy” (4 buy, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Innoviva expected to earn?
Analysts expect EPS of $0.86 for the fiscal year ending December 31, 2026 and $2.14 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.